Clinical Trials

Radium-223 (Alpharadin) in Men with Castration-Resistant Prostate Cancer and Bone Metastases

Protocol
12-199
Full Title
Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis
Purpose

Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies (¿castration-resistant¿ prostate cancer). It is not unusual for castration-resistant prostate cancer to metastasize to the bone and cause pain.

The purpose of this study is to evaluate the safety and effectiveness of a treatment called Alpharadin in men with castration-resistant prostate cancer who have bone metastases. Alpharadin is radium-223 chloride, a liquid that contains a radioactive element that specifically targets prostate cancer that has metastasized to bone. The radiation that radium-223 gives out travels only a very short distance in the body, and therefore acts mainly on the areas of the bones that require treatment: bone metastases.

Investigator
Michael J. Morris, MD
Michael J. Morris - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have castration-resistant prostate cancer that has spread to the bones and is causing bone pain.
  • Patients may not be candidates for docetaxel treatment.
  • Patients may not have had radiation therapy to more than 25 percent of the bone marrow, nor prior treatment with radionuclides.
  • At least 4 weeks must have passed since completion of any prior chemotherapy and entry into the study.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Michael Morris at 646-422-4469.

Disease(s)
Prostate Cancer
Prostate Cancer: Metastatic Disease after Hormone-Reducing Therapy
Locations
ClinicalTrials.gov
Related Diseases